Wegovy

Wegovy, a weight-loss drug developed by Novo Nordisk, is currently a prominent subject in news due to a confluence of factors. Its active ingredient, semaglutide (also in Ozempic), is seeing patent expirations in key markets like India, potentially leading to cheaper generic versions. This, coupled with initiatives to lower drug prices (e.g., in the US), is predicted to impact Novo Nordisk's revenue. Simultaneously, studies are raising safety concerns, such as a potentially higher risk of sudden sight loss compared to Ozempic. The emergence of competing drugs, including oral GLP-1 options like orforglipron and next-generation treatments, further intensifies the competitive landscape. Experts caution against relying solely on weight-loss drugs to solve obesity crises, highlighting the importance of comprehensive approaches. The potential for counterfeit versions, especially as oral forms become available, also raises concerns about public safety and regulatory enforcement.